[HTML][HTML] Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE–Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - The Lancet Regional …, 2022 - thelancet.com
Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE-Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - Lancet regional …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Previous Randomised controlled trials (RCT) evaluating chloroquine and
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
[PDF][PDF] Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE− Coalition V): A double-blind, multicentre, randomised …
A Avezum, GBF Oliveira, H Oliveira, RC Lucchetta… - Health, 2022 - researchgate.net
Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in nonhospitalised COVID-19 patients have found no significant …
and hydroxychloroquine in nonhospitalised COVID-19 patients have found no significant …
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE-Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - Lancet Regional …, 2022 - europepmc.org
Background Previous Randomised controlled trials (RCT) evaluating chloroquine and
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
[PDF][PDF] Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE− Coalition V): A double-blind, multicentre, randomised …
A Avezum, GBF Oliveira, H Oliveira, RC Lucchetta… - Health, 2022 - hcor.com.br
Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in nonhospitalised COVID-19 patients have found no significant …
and hydroxychloroquine in nonhospitalised COVID-19 patients have found no significant …
[HTML][HTML] Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE–Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - Lancet Regional …, 2022 - ncbi.nlm.nih.gov
Background Previous Randomised controlled trials (RCT) evaluating chloroquine and
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
[HTML][HTML] Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE–Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - The Lancet Regional …, 2022 - Elsevier
Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE-Coalition V): A double-blind, multicentre, randomised …
Á Avezum, GBF Oliveira, H Oliveira… - Lancet Regional …, 2022 - europepmc.org
Background Previous Randomised controlled trials (RCT) evaluating chloroquine and
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …
hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …